The Zhitong Finance App learned that Nomura released a research report saying that ten mainland regulators released the “Fifteenth Five-Year Plan” for the pharmaceutical industry (2026-2030) before opening the market on September 18, reaffirming the new position of the pharmaceutical industry as an emerging pillar industry and highlighting innovation and globalization, which is expected to benefit innovative pharmaceutical companies and CRDMOs; the bank maintained a “buy” rating for Cinda Biotech (01801), Columbotai Bio-B (06990), and Pharmaceutical Federation (02268).
According to the bank, the plan was issued by ten regulators, including the Ministry of Industry and Information Technology, the National Development and Reform Commission, the National Drug Administration, and the National Health Insurance Administration, and proposed a number of quantitative targets, including that the average R&D expenditure of listed pharmaceutical companies should account for more than 10% of sales (currently estimated at about 8%), first-in-class (FIC) drugs account for more than 25% of the global share (currently only about ten percentage points), and the sales growth rate of innovative drugs is higher than 20% (far faster than the overall industry growth of about 8% during the “14th Five-Year Plan” period, and the overall industry figure is not mentioned this time), and global sales The number of $1 billion drugs exceeds 5 (currently about 2 to 3).
Priority areas include siRNA/ASO, proTac/molecular glues, PDC, radioligand conjugates, dual-antibody/polyantibodies, ADC/RDC/AOC, CAR-T (including in vivo and generic), iPSC, AAV, LNP, mRNA vaccines, and medical devices such as degradable stents, single-cell sequencing, AI pathology, surgical robots, closed-loop insulin pumps, brain-computer interface exoskeletons, etc., as well as AI molecular design and DNA digital storage.
The bank believes that compared to the “14th Five-Year Plan”, innovation and globalization have been placed at the core, reflecting the rapid development of the industry in recent years and the increase in global competitiveness. Once more stakeholders take action and introduce more detailed policies, Cinda Biotech, PharmacomingKangde, and Pharmacoming.com will benefit.